Burning Rock Biotech Limited (BNR)

Market Cap	45.40M
Revenue (ttm)	72.11M
Net Income (ttm)	-32.88M
Shares Out	10.77M
EPS (ttm)	-3.16
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	15,945
Open	3.920
Previous Close	3.980
Day's Range	3.920 - 4.448
52-Week Range	2.180 - 7.900
Beta	0.75
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 21, 2025

About BNR

Burning Rock Biotech Limited primarily develops and sells cancer therapy selection tests in the People's Republic of China. It operates through three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company offers next-generation sequencing (NGS) based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various cancer types, including pan-cancer, lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, and ovari...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Jun 12, 2020
• Employees: 674
• Stock Exchange: NASDAQ
• Ticker Symbol: BNR
• Website: https://www.brbiotech.com

Financial Performance

In 2024, Burning Rock Biotech's revenue was 515.82 million, a decrease of -4.02% compared to the previous year's 537.44 million. Losses were -346.63 million, -46.97% less than in 2023.

Financial numbers in CNY